These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 29875101)

  • 1. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in
    Cortes JE; Tallman MS; Schiller GJ; Trone D; Gammon G; Goldberg SL; Perl AE; Marie JP; Martinelli G; Kantarjian HM; Levis MJ
    Blood; 2018 Aug; 132(6):598-607. PubMed ID: 29875101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
    Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
    Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study.
    Takahashi T; Usuki K; Matsue K; Ohno H; Sakura T; Imanaka R; Murakami M; Ohwada S; Takagi T; Sakajiri S
    Int J Hematol; 2019 Dec; 110(6):665-674. PubMed ID: 31473943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
    Cortes JE; Khaled S; Martinelli G; Perl AE; Ganguly S; Russell N; Krämer A; Dombret H; Hogge D; Jonas BA; Leung AY; Mehta P; Montesinos P; Radsak M; Sica S; Arunachalam M; Holmes M; Kobayashi K; Namuyinga R; Ge N; Yver A; Zhang Y; Levis MJ
    Lancet Oncol; 2019 Jul; 20(7):984-997. PubMed ID: 31175001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
    Cortes JE; Kantarjian H; Foran JM; Ghirdaladze D; Zodelava M; Borthakur G; Gammon G; Trone D; Armstrong RC; James J; Levis M
    J Clin Oncol; 2013 Oct; 31(29):3681-7. PubMed ID: 24002496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study.
    Usuki K; Handa H; Choi I; Yamauchi T; Iida H; Hata T; Ohwada S; Okudaira N; Nakamura K; Sakajiri S
    Int J Hematol; 2019 Dec; 110(6):654-664. PubMed ID: 31359361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quizartinib for the treatment of acute myeloid leukemia.
    Garcia-Horton A; Yee KW
    Expert Opin Pharmacother; 2020 Dec; 21(17):2077-2090. PubMed ID: 32772726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
    Ganguly S; Cortes JE; Krämer A; Levis MJ; Martinelli G; Perl AE; Russell NH; Arunachalam M; Santos CD; Gammon G; Lesegretain A; Mires DE; Pham H; Wang Y; Khaled SK
    Transplant Cell Ther; 2021 Feb; 27(2):153-162. PubMed ID: 33017662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Erba HP; Montesinos P; Kim HJ; Patkowska E; Vrhovac R; Žák P; Wang PN; Mitov T; Hanyok J; Kamel YM; Rohrbach JEC; Liu L; Benzohra A; Lesegretain A; Cortes J; Perl AE; Sekeres MA; Dombret H; Amadori S; Wang J; Levis MJ; Schlenk RF;
    Lancet; 2023 May; 401(10388):1571-1583. PubMed ID: 37116523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
    Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
    BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports.
    Martínez-Cuadrón D; Rodríguez-Macías G; Rodríguez-Veiga R; Boluda B; Montesinos P
    Clin Drug Investig; 2020 Mar; 40(3):227-235. PubMed ID: 31912423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant.
    Sandmaier BM; Khaled S; Oran B; Gammon G; Trone D; Frankfurt O
    Am J Hematol; 2018 Feb; 93(2):222-231. PubMed ID: 29090473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China.
    Qi J; Choi I; Ota S; Ichikawa S; Fujishima N; Iida H; Sugiura I; Sugiura K; Murata Y; Inoue H; Ohwada S; Wang J
    Clin Pharmacol Drug Dev; 2024 May; 13(5):560-571. PubMed ID: 38284515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of quizartinib in the treatment of acute myeloid leukemia.
    Ostronoff F; Estey E
    Expert Opin Investig Drugs; 2013 Dec; 22(12):1659-69. PubMed ID: 24070241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.
    Altman JK; Foran JM; Pratz KW; Trone D; Cortes JE; Tallman MS
    Am J Hematol; 2018 Feb; 93(2):213-221. PubMed ID: 29139135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
    Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
    Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia.
    Paul S; DiPippo AJ; Ravandi F; Kadia TM
    Future Oncol; 2019 Dec; 15(34):3885-3894. PubMed ID: 31559849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
    Swaminathan M; Kantarjian HM; Levis M; Guerra V; Borthakur G; Alvarado Y; DiNardo CD; Kadia T; Garcia-Manero G; Ohanian M; Daver N; Konopleva M; Pemmaraju N; Ferrajoli A; Andreeff M; Jain N; Estrov Z; Jabbour EJ; Wierda WG; Pierce S; Pinsoy MR; Xiao L; Ravandi F; Cortes JE
    Haematologica; 2021 Aug; 106(8):2121-2130. PubMed ID: 33853292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quizartinib (AC220): a promising option for acute myeloid leukemia.
    Zhou F; Ge Z; Chen B
    Drug Des Devel Ther; 2019; 13():1117-1125. PubMed ID: 31114157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.
    Jaramillo S; Le Cornet L; Kratzmann M; Krisam J; Görner M; Hänel M; Röllig C; Wass M; Scholl S; Ringhoffer M; Reichart A; Steffen B; Kayser S; Mikesch JH; Schaefer-Eckart K; Schubert J; Geer T; Martin S; Kieser M; Sauer T; Kriegsmann K; Hundemer M; Serve H; Bornhäuser M; Müller-Tidow C; Schlenk RF
    Trials; 2023 Sep; 24(1):591. PubMed ID: 37715270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.